# PT-141 Dosage: What Clinical Research Shows **By TelosRX Editorial Team** ยท 2026-08-14 **The only PT-141 dosage defined in FDA-approved labeling is bremelanotide 1.75 mg subcutaneously, taken at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours. Compounded [PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141) is always provider-determined.** That number does not come from forums or supplier catalogs. It comes from one document: the prescribing information for Vyleesi, the branded bremelanotide autoinjector the FDA approved in 2019. ## Where the 1.75 mg Figure Comes From PT-141 is the research name for bremelanotide. Same molecule, different label. Vyleesi is the branded version, and the only form of bremelanotide the FDA has approved. That approval covers a narrow group: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The label states plainly that it is not indicated for postmenopausal women or men, and not indicated to enhance sexual performance. So every credible PT-141 peptide dosage figure in circulation traces back to one approved product studied in one population. For the underlying pharmacology, see our guide to [what PT-141 is and how bremelanotide works](https://www.telosrx.com/blogs/peptides/what-is-pt-141-bremelanotide-guide). ## What the Approved Label Actually Specifies The [Vyleesi prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) is short and specific on dosing. These are published parameters for an approved product, not a protocol for anyone to follow on their own. Parameter What the Vyleesi label states Dose 1.75 mg bremelanotide in 0.3 mL, single-dose autoinjector Route Subcutaneous injection, abdomen or thigh Timing As needed, at least 45 minutes before anticipated sexual activity Maximum frequency Not more than one dose within 24 hours Monthly ceiling More than 8 doses per month is not recommended Reassessment point Discontinue after 8 weeks if the patient does not report an improvement in symptoms Contraindications Uncontrolled hypertension or known cardiovascular disease Approved population Premenopausal women with acquired, generalized HSDD Note the words **as needed**. Bremelanotide was designed and studied as an episodic, on-demand medicine, not a daily maintenance peptide. ## How That Dose Was Used in the RECONNECT Trials The 1.75 mg figure was carried into approval by the RECONNECT program: two phase 3 randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD, registered as [NCT02333071](https://clinicaltrials.gov/study/NCT02333071) and its companion study NCT02338960. Participants used the dose on demand rather than on a fixed schedule, across a double-blind phase followed by an open-label extension. The co-primary endpoints covered sexual desire and the distress associated with low desire. The safety data from those trials is where the ceiling numbers come from. Nausea was reported by 40 percent of patients receiving up to eight doses monthly, and focal hyperpigmentation was reported by about 1 percent at that same frequency. The monthly limit reflects the exposure that was actually studied, not an arbitrary cap. [Published RECONNECT data](https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/) covers the efficacy findings in detail. Reading dosing research is useful. Having a licensed provider apply it to your own health history is the part that matters. [See PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141) ## Why the Window Is 45 Minutes Bremelanotide is a melanocortin receptor agonist acting at MC3R and MC4R receptors in the hypothalamus, upstream of the blood-flow pathway that PDE5 inhibitors target. Central activity takes time to establish after a subcutaneous dose, which is why the label frames timing as at least 45 minutes ahead rather than a few minutes before. Because the mechanism is central, it does not strictly require sexual stimulation to initiate a response, a distinction we unpack in [PT-141 versus Viagra and Cialis](https://www.telosrx.com/blogs/peptides/pt-141-vs-viagra-cialis). Onset is individual. Earlier phase 2 work in men reported erectile responses in roughly the 30 to 60 minute range, which fits a centrally acting compound rather than a fast vascular one. ## Why Compounded PT-141 Protocols Vary **Compounded PT-141 is not FDA-approved.** It is prepared by licensed US compounding pharmacies under federal compounding regulations, which means no single approved label governs its strength, concentration or schedule. Vial concentration, reconstitution volume and available formulations can differ between pharmacies and between states. A figure that applies to one preparation does not transfer cleanly to another. Telos Rx offers compounded PT-141 as an as-needed subcutaneous dose taken ahead of anticipated intimacy, subject to medical approval by a licensed provider. Formulations may vary by state. ## What a Provider Weighs Before Prescribing Deciding how much PT-141 is appropriate is a clinical judgment, not arithmetic. A reviewing provider reads a health history that includes: - **Blood pressure and cardiovascular history.** The label lists uncontrolled hypertension and known cardiovascular disease as contraindications. A transient rise in blood pressure with a modest decrease in heart rate follows each dose and usually resolves within 12 hours. - **Which population you fall into.** The approved indication is premenopausal women with acquired, generalized HSDD. Everything else is off-label and reasoned from weaker evidence. - **Nausea tolerance.** Nausea was the most commonly reported effect in trials and led some participants to stop. Providers raise it directly rather than treating it as a footnote. - **Skin and pigmentation history.** Focal hyperpigmentation has been reported with repeated dosing, with higher risk in people with darker skin and with more frequent use. - **Other medications.** Bremelanotide can slow gastric emptying and affect absorption of oral medicines, and it substantially reduces exposure to orally administered naltrexone. - **Pregnancy status and contraception.** The approved labeling advises discontinuation if pregnancy is suspected. - **Expected frequency of use.** Someone anticipating occasional use sits in a different risk picture than someone near the monthly ceiling. A fuller breakdown of the trial safety findings sits in our guide to [PT-141 side effects and what trials reported](https://www.telosrx.com/blogs/peptides/pt-141-side-effects-safety). ## Dosage in Men Is Off-Label Territory There is no FDA-approved bremelanotide dose for men. The Vyleesi label explicitly excludes men from its indication, so any male protocol is off-label and rests on earlier-phase research rather than a phase 3 dataset. An intranasal formulation was studied earlier in development but was not carried forward to approval, because of blood pressure findings tied to that route. The subcutaneous form is the one that reached approval, a history we cover in [PT-141 nasal spray versus injection](https://www.telosrx.com/blogs/peptides/pt-141-nasal-spray-vs-injection). What the male evidence does not provide is a validated dose. See [PT-141 for men](https://www.telosrx.com/blogs/peptides/pt-141-for-men-research-guide) for that research picture, and [PT-141 for women](https://www.telosrx.com/blogs/peptides/pt-141-for-women-hsdd-guide) for the HSDD context. ## Why PT-141 Is Never Self-Dosed Everything above reports what published labeling and trial protocols specify. None of it is a protocol for a reader to run alone. The reason is practical. Those parameters only hold inside the population that was studied, with the exclusions that trial applied. People with uncontrolled hypertension or known cardiovascular disease were kept out of the trials, and the approved label carries that exclusion forward as a contraindication. Working out which side of that line you sit on is a clinical assessment. Telos Rx runs that assessment asynchronously. You complete a written intake, a licensed provider reviews your history, and PT-141 is prescribed only when it is appropriate. Approval is not guaranteed. For the wider evidence picture, see our review of the [research-backed benefits of PT-141](https://www.telosrx.com/blogs/peptides/pt-141-bremelanotide-benefits-research-guide). ## Frequently Asked Questions ### How much PT-141 is in a standard dose? The only standardized figure is the approved one: Vyleesi delivers 1.75 mg of bremelanotide in 0.3 mL from a single-dose subcutaneous autoinjector. Compounded PT-141 is not FDA-approved and has no single fixed strength, so the amount in any given preparation is determined by the prescribing provider and the pharmacy filling it. ### How long before sex is PT-141 taken in clinical research? The approved label specifies administration at least 45 minutes before anticipated sexual activity, and the RECONNECT trials used that same on-demand timing. Because bremelanotide acts centrally rather than on blood flow, onset is slower than a vascular medication. Individual response times vary, which is one reason timing is set with a provider. ### Can PT-141 be used every day? No. The Vyleesi label states not more than one dose within 24 hours, and that more than eight doses per month is not recommended. It was studied as an as-needed medicine rather than a daily one. Daily dosing was also associated with higher hyperpigmentation risk in reported safety data. ### Is there a standard PT-141 dosage for men? There is no FDA-approved dose for men. Vyleesi is approved only for premenopausal women with acquired, generalized HSDD, and its label states it is not indicated for men. Phase 2 research in men with erectile dysfunction showed dose-dependent responses, but that work never produced an approved male dosing standard. ### Why do compounded PT-141 doses differ from Vyleesi? Compounded PT-141 is prepared by licensed US compounding pharmacies under federal compounding regulations rather than manufactured under an FDA-approved label. Concentration, volume and formulation can differ between pharmacies and states, so a number that describes one preparation may not describe another. This is why online dosing charts are unreliable. ### Who decides what PT-141 dosage is appropriate? A licensed provider does, after reviewing your written intake and health history. That review weighs blood pressure and cardiovascular history, current medications, pregnancy status and expected frequency of use. At Telos Rx the process is asynchronous, and approval is subject to medical evaluation by a licensed provider rather than guaranteed. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ If low desire is the thing you would actually like looked at, the next step is a written intake rather than a dosing chart. See [compounded PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141), then start your online visit: [men start here](https://start.telosrx.com/start-online-visit/pt141men) or [women start here](https://start.telosrx.com/start-online-visit/pt141women). A licensed provider reviews every request. **Tags:** bremelanotide, HSDD, libido, peptides, PT-141, PT-141 dosage, sexual health, Vyleesi --- > Source: [Telos RX](https://www.telosrx.com/blogs/peptides/pt-141-dosage-guide)